Live Breaking News & Updates on Head of international at rhythm

Stay informed with the latest breaking news from Head of international at rhythm on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Head of international at rhythm and stay connected to the pulse of your community

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

BOSTON, Feb. 07, 2024 -- Rhythm Pharmaceuticals, Inc. , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare...

Canada , United-states , Boston , Massachusetts , Italy , United-kingdom , Italian , Adam-daley , David-connolly , Yann-mazabraud , Drug-administration , Nasdaq

Rhythm Pharmaceuticals Announces Completion of Screening

-- Phase 3 hypothalamic obesity top-line data expected in 1H2025 -- -- Positive reimbursement decision achieved for IMCIVREE® (setmelanotide) to treat...

Spain , United-kingdom , Boston , Massachusetts , United-states , David-meeker , Yann-mazabraud , David-connolly , Adam-daley , Nasdaq , Ministry-of-health , Rhythm-pharmaceuticals-inc

Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

-- Phase 3 hypothalamic obesity top-line data expected in 1H2025 -- -- Positive reimbursement decision achieved for IMCIVREE® to treat patients with Bardet-Biedl syndrome and POMC/LEPR...

United-kingdom , United-states , Boston , Massachusetts , Spain , Adam-daley , Yann-mazabraud , David-connolly , David-meeker , Corporate-communications , United-kingdom-medicines-healthcare-products-regulatory-agency , Berry-company-public-relations

Rhythm Pharmaceuticals (RYTM) Provides Business Update

Rhythm Pharmaceuticals (RYTM) Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , United-states , Boston , Massachusetts , Spain , David-meeker , Yann-mazabraud , Rhythm-pharmaceuticals-inc , Head-of-international-at-rhythm , Nasdaq , European-union , Ministry-of-health

Rhythm Pharmaceuticals (RYTM) Granted Orphan Drug Designation in EU for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals (RYTM) Granted Orphan Drug Designation in EU for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Germany , France , Netherlands , Spain , United-kingdom , Italy , Yann-mazabraud , European-union , Head-of-international-at-rhythm , European-medicines-agency , Rhythm-pharmaceuticals-inc , Nasdaq

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Germany , United-kingdom , France , Boston , Massachusetts , United-states , Netherlands , Canada , Italy , Spain , David-connolly , Adam-daley

Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

IMCIVREE is eligible for federal reimbursement by Statutory Health Insurances in GermanyBOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical

France , Spain , United-states , Netherlands , Germany , Italy , Boston , Massachusetts , Berlin , United-kingdom , German , Yann-mazabraud

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

Boston , Massachusetts , United-states , United-kingdom , France , French , Great-britain , Yann-mazabraud , Health-products-safety , France-national-health-system , French-national-agency-for-medicines , Nasdaq